MORGAN STANLEY PLC/CALL/AMGEN/270/0.1/20.12.24 | Market Closed - Börse Stuttgart 19:31:34 05/07/2024 BST | ||
| 4.91 EUR | +2.51% |
|
| Current month | -3.35% | ||
| 1 month | +0.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 4.91 | +2.51% |
| 04/07/24 | 4.79 | -0.62% |
| 03/07/24 | 4.82 | -5.49% |
| 02/07/24 | 5.1 | +0.99% |
| 01/07/24 | 5.05 | -0.59% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:31 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB16YK |
| ISIN | DE000MB16YK3 |
| Date issued | 05/12/2022 |
| Strike | 270 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 6.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.4 € |
|---|---|
| Lowest since issue | 0.67 € |
| Spread | 0.03 € |
| Spread % | 0.60% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.9
USD
Average target price
316.4
USD
Spread / Average Target
+1.79%
- Stock Market
- Warrants
- Warrant
